Table 2.
Univariable and multivariable logistic regression analysis of factors associated with vedolizumab endoscopic response at week 16
| Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|
| Baseline characteristics |
Response, yes n = 60 (%) |
Response, no n = 54 (%) |
P‐value | OR [95% CI] | P‐value |
| Sex | |||||
| Male | 20 (33) | 24 (44) | 0.25 | — | — |
| Smoking | |||||
| Yes | 14 (23) | 8 (15) | 0.23 | — | — |
| IBD type | |||||
| CD | 32 (53) | 36 (67) | 0.18 | — | — |
| UC | 28 (47) | 18 (33) | 0.52 [0.24–1.15] | 0.11 | |
| Prior surgery for CD | 17 (28) | 17 (32) | 0.84 | — | — |
| Steroid induction | 35 (58) | 40 (74) | 0.11 | 1.87 [0.83–4.23] | 0.13 |
| Anti‐TNFα refractory | 48 (81) | 45 (83) | 0.81 | — | — |
| Endoscopic disease severity at baseline | |||||
| Mild | 8 (13) | 8 (15) | 0.12 † | — | — |
| Moderate | 36 (60) | 24 (44) | — | — | |
| Severe | 16 (27) | 22 (41) | 1.99 [0.87–4.55] | 0.10 † | |
| Disease location CD | |||||
| Ileal | 3 (9) | 3 (8) | 0.55 ‡ | — | — |
| Colonic | 5 (16) | 8 (22) | — | — | |
| Ileocolonic | 24 (75) | 25 (69) | — | — | |
| Upper GI | 4 (6) | 2 (4) | — | — | |
| Disease location UC | |||||
| Proctitis | 0 (0) | 0 (0) | 0.36 | — | — |
| Left‐sided | 12 (43) | 5 (28) | — | — | |
| Pancolitis | 16 (57) | 13 (72) | — | — | |
| Perianal disease | |||||
| Yes | 6 (10) | 13 (24) | 0.18 | — | — |
†
Severe endoscopic disease activity versus no severe endoscopic disease activity.
‡
Colonic versus ileal and ileocolonic disease.
Univariable and multivariable analysis showed no significant associations between clinical baseline parameters and endoscopic response. CD, Crohn's disease; CI, confidence interval; GI, gastrointestinal disease activity; IBD, inflammatory bowel disease; N, numbers; OR, odds ratio; TNFα, tumor necrosis factor alpha; UC, ulcerative colitis.